ZIVO Bioscience (ZIVO) 10-Q 19 Oct 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - $ / shares	Oct. 19, 2017	Sep. 30, 2017
Details
Registrant Name		Zivo Bioscience, Inc.
Registrant CIK		1,101,026
SEC Form		10-Q
Period End date		Sep. 30, 2017
Fiscal Year End		--12-31
Trading Symbol		zivo
Tax Identification Number (TIN)		870,699,977
Number of common stock shares outstanding	140,906,061
Filer Category		Smaller Reporting Company
Current with reporting		Yes
Voluntary filer		No
Well-known Seasoned Issuer		No
Amendment Flag		false
Document Fiscal Year Focus		2,017
Document Fiscal Period Focus		Q3
Entity Incorporation, State Country Name		Nevada
Entity Address, Address Line One		2804 Orchard Lake Rd., Suite 202,
Entity Address, City or Town		Keego Harbor
Entity Address, State or Province		MI
Entity Address, Postal Zip Code		48,320
City Area Code		(248)
Local Phone Number		452 9866
Entity Listing, Par Value Per Share	$ 0.001

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (September 30, 2017 unaudited) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
CURRENT ASSETS:
Cash	$ 1,224,581	$ 506,986
Prepaid Expenses	90,831	13,437
Total Current Assets	1,315,412	520,423
PROPERTY AND EQUIPMENT, NET	0	18,750
OTHER ASSETS:
Deferred Finance Costs, net	113,769	198,119
Total Other Assets	113,769	198,119
TOTAL ASSETS	1,429,181	737,292
CURRENT LIABILITIES:
Accounts Payable	635,039	666,365
Due to Related Party	478,534	319,234
Loans Payable, Related Parties	344,019	245,979
ConvertibleDebenturesPayable, less discount	16,186,051	6,886,710
Accrued Interest	1,163,827	2,659,574
Accrued Liabilities - Other	10,000	404,618
Total Current Liabilities	18,817,470	11,182,480
LONG TERM LIABILITIES:
Total Long Term Liabilities	650,000	3,176,047
TOTAL LIABILITIES	19,467,470	14,358,527
STOCKHOLDERS' DEFICIT:
Common Stock, Value	140,906	136,745
Additional Paid-In Capital	41,753,140	40,016,059
Accumulated deficit	(59,932,335)	(53,774,039)
Total Stockholders' Deficit	(18,038,289)	(13,621,235)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	1,429,181	737,292
Convertible Debentures Payable, less Discount	$ 650,000	$ 3,176,047

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (September 30, 2017 unaudited) - Parenthetical - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Details
Convertible Debentures Payable, Current, Discount	$ 566,701	$ 500,490
Convertible Debentures Payable, Non-current, Discount	$ 0	$ 73,953
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	450,000,000	450,000,000
Common Stock, Shares, Issued	140,906,061	136,745,347
Common Stock, Shares, Outstanding	140,906,061	136,745,347

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Statement of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Details
REVENUES:	$ 0	$ 0	$ 0	$ 0
COSTS AND EXPENSES:
General and Administrative	245,959	195,481	674,529	600,150
Professional fees and Consulting expense	1,264,111	355,941	1,703,725	1,646,669
Research and Development	550,549	125,695	1,355,085	600,966
Total Costs and Expenses	2,060,619	677,117	3,733,339	2,847,785
LOSS FROM OPERATIONS	(2,060,619)	(677,117)	(3,733,339)	(2,847,785)
OTHER INCOME (EXPENSE):
Loss on Extinguishment of Debt	0	0	(406,482)	0
Other income	7,394	0	7,394	0
Amortization of Debt Discount	(121,618)	(170,757)	(427,626)	(1,119,875)
Amortization of Deferred Finance Costs	(28,117)	0	(84,350)	0
Financing Costs	(135,000)	(27,000)	(189,000)	(94,500)
Finance Costs paid in stocks and warrants - related party	(90,000)	(18,000)	(126,000)	(63,000)
Interest expense	(35,446)	(600)	(104,926)	(1,800)
Interest Expense, Related Parties	(405,112)	(246,907)	(1,093,967)	(700,469)
Total Other Income (Expense)	(807,899)	(463,264)	(2,424,957)	(1,979,644)
Net Loss	$ (2,868,518)	$ (1,140,381)	$ (6,158,296)	$ (4,827,429)
BASIC AND DILUTED LOSS PER SHARE	$ (0.02)	$ (0.01)	$ (0.04)	$ (0.04)
WEIGHTED AVERAGE BASIC AND DILUTED SHARES OUTSTANDING	140,159,788	133,507,211	138,652,686	132,879,550

Unaudited Condensed Consolidat5

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Net Cash Provided by (Used in) Operating Activities
Net Loss	$ (6,158,296)	$ (4,827,429)
Adjustments to reconcile net loss to net cash used by operating activities:
Stock and warrants issued for services rendered - related party	10,463	10,857
Stock and warrants issued for services rendered	1,160,157	1,270,060
Loss on Extinguishment of Debt	406,482	0
Warrants issued for Directors' Fees	166,668	69,713
Stock and warrants issued for financing costs - related party	126,000	63,000
Amortization of deferred finance costs	84,350	0
Amortization of bond discount	427,626	1,119,875
Depreciation expense	18,750	18,750
Changes in assets and liabilities:
(Increase) in prepaid expenses	(77,394)	(16,916)
(Decrease) in accounts payable	(31,326)	(290,700)
Increase in due to related party	159,300	94,500
Increase in accrued liabilities and interest	826,775	764,667
Net Cash Provided by (Used in) Operating Activities	(2,880,445)	(1,723,623)
Cash Flows from Investing Activities:	0	0
Net Cash Provided by (Used in) Financing Activities
Proceeds of Loan Payable, related party	98,040	2,315
Deferred Finance Costs	0	(60,000)
Proceeds from issuance of 11% convertible debentures	3,500,000	2,350,000
Net Cash Provided by (Used in) Financing Activities	3,598,040	2,292,315
Increase (Decrease) in Cash	717,595	568,692
Cash and Cash Equivalents, at Carrying Value, Beginning Balance	506,986	16,589
Cash and Cash Equivalents, at Carrying Value, Ending Balance	1,224,581	585,281
Supplemental Cash Flow Information
Interest Paid	0	0
Income Taxes Paid	$ 0	$ 0

Additional Cash Flow Elements a

Additional Cash Flow Elements and Supplemental Cash Flow Information - USD ($)	3 Months Ended
	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016
Details
Discounts on 11% convertible debentures	$ 155,065	$ 70,388	$ 24,218
Debt discount for a restructuring fee related to the debt extinguishment		600,000
Reclassification of Accrued Interest to 11% Convertible Debentures		2,694,639
Common stock issued in payment of an accrued liability		$ 22,500
Convertible debt converted into shares	$ 30,000
Discounts on 11% convertible debentures				$ 186,744	$ 724,280
Common stock warrants issued as deferred finance costs			$ 50,371

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	9 Months Ended
	Sep. 30, 2017
Notes
Note 1 - Basis of Presentation	NOTE 1 – BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the information set forth therein. These consolidated financial statements are condensed, and therefore do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s December 31, 2016 consolidated audited financial statements and Notes thereto included in the Annual Report on Form 10-K filed with the SEC on March 31, 2017. The results of operations for the nine months ended September 31, 2017 are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2017, or any other period. The Company incurred a net loss of $6,158,296 for the nine months ended September 31, 2017. In addition, the Company had a working capital deficiency of $17,502,058 and a stockholders’ deficit of $18,038,289 at September 31, 2017. These factors continue to raise substantial doubt about the Company's ability to continue as a going concern. During the nine months ended September 31, 2017, the Company raised $3,500,000 from the issuance of convertible debt. There can be no assurance that the Company will be able to raise additional capital. The accompanying unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Notes
Note 2 - Summary of Significant Accounting Policies	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly-owned subsidiaries, Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., WellMetris, LLC, and Zivo Biologic, Inc. All significant intercompany transactions and accounts have been eliminated in consolidation. Accounting Estimates The Company’s condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements and reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management uses its best judgment in valuing these estimates and may, as warranted, solicit external professional advice and other assumptions believed to be reasonable. Cash and Cash Equivalents For the purpose of the statements of cash flows, cash equivalents include time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. Cash equivalents consist of highly liquid investments with an original maturity of three months or less when purchased. At September 30, 2017, the Company did not have any cash equivalents. Property and Equipment Property and equipment consists of furniture and office equipment and are carried at cost less allowances for depreciation and amortization. Depreciation and amortization is determined by using the straight-line method over the estimated useful lives of the related assets. Repair and maintenance costs that do not improve service potential or extend the economic life of an existing fixed asset are expensed as incurred. Deferred Financing Costs The Company follows authoritative guidance for accounting for financing costs as it relates to convertible debt issuance cost. These costs are deferred and amortized over the term of the debt period or until redemption of the convertible debentures. Amortization of deferred financing costs amounted to $84,350 and $0 for the nine months ended September 30, 2017 and 2016, respectively. Revenue Recognition For revenue from product sales, the Company recognizes revenue in accordance with Staff Accounting Bulletin No. 104, “Revenue Recognition” (“SAB No. 104”), which superseded Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements” (“SAB No. 101”). SAB No. 104 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgment regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. For nine months ended September 30, 2017 and 2016, the Company had no revenue. Shipping and Handling Costs Shipping and handling costs are expensed as incurred. For the nine months ended September 30, 2017 and 2016, no shipping and handling costs were incurred. Research and Development Research and development costs are expensed as incurred. The majority of the Company's research and development costs consist of clinical study expenses. These consist of fees, charges, and related expenses incurred in the conduct of clinical studies conducted with Company products by independent outside contractors. External clinical studies expenses were approximately $1,355,000 and $601,000 for the nine months ended September 30, 2017 and 2016, respectively. Stock Based Compensation We account for stock-based compensation in accordance with FASB ASC 718, Compensation – Stock Compensation. During the nine months ended September 30, 2017 and 2016, warrants were granted to employees and consultants of the Company. As a result of these grants, the Company recorded compensation expense of $1,337,289 and $1,175,630 for these periods, respectively. The fair value of warrants was estimated on the date of grant using the Black-Scholes option-pricing model based on the following weighted average assumptions: Nine Months Ended September 30, 2017 2016 Expected volatility 175.05% to 177.58% 158.53% to 172.80% Expected dividends 0% 0% Expected term 5 years 5 years Risk free rate 1.63% to 1.93% .71% to .97% The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, option-pricing models require the input of highly subjective assumptions, including the expected stock price volatility. Because the Company’s employee warrants have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion the existing models may not necessarily provide a reliable single measure of the fair value of the warrants. Loss Per Share Basic loss per share is computed by dividing the Company’s net loss by the weighted average number of common shares outstanding during the period presented. Diluted loss per share is based on the treasury stock method and includes the effect from potential issuance of common stock such as shares issuable pursuant to the exercise of warrants and conversions of debentures. Potentially dilutive securities as September 30, 2017, consisted of 186,314,359 common shares issuable upon the conversion of convertible debentures and related accrued interest and 52,151,754 common shares issuable upon the exercise of outstanding warrants. Potentially dilutive securities as of September 30, 2016, consisted of 102,036,360 common shares issuable upon the conversion of convertible debentures and related accrued interest and 30,167,488 common shares issuable upon the exercise of outstanding warrants. For the nine months ended September 30, 2017 and 2016 diluted and basic weighted average shares are the same, as potentially dilutive shares are anti-dilutive. Advertising Advertising costs are charged to operations when incurred. There were no advertising costs for the nine months ended September 30, 2017 and 2016. Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company, from time to time, maintains cash balances at financial institutions which exceed the current Federal Deposit Insurance Corporation (“FDIC”) limit of $250,000. Reclassifications Certain items in these consolidated financial statements have been reclassified to conform to the current period presentation. Future Impact of Recently Issued Accounting Standards In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), “Revenue from Contracts with Customers.” ASU 2014-09 superseded the revenue recognition requirements in “Revenue Recognition (Topic 605)” and requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflect the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is not permitted. ASU 2014-09 is not expected to have a material impact on the Company’s financial position or results of operations. In August 2014, the FASB issued Accounting Standards Update 2014-15 (ASU 2014-15) “Presentation of Financial Statements – Going Concern (Subtopic 205-40).” The amendments in this Update are effective for the annual period ending after December 15, 2015, and for annual periods and interim periods thereafter. Early application is permitted. This Update had no effect on the Company’s financial position and results of operations for the year ended December 31, 2016. Management does not believe there would have been a material effect on the accompanying financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.

Note 3 - Property and Equipment

Note 3 - Property and Equipment	9 Months Ended
	Sep. 30, 2017
Notes
Note 3 - Property and Equipment	NOTE 3 - PROPERTY AND EQUIPMENT Property and equipment at September 30, 2017 and December 31, 2016 consisted of the following: September 30, 2017 December 31, 2016 (Unaudited) Furniture and fixtures $ 20,000 $ 20,000 Equipment 80,000 80,000 100,000 100,000 Less accumulated depreciation and amortization (100,000) (81,250) $ 0 $ 18,750 Depreciation and amortization was $18,750 and $18,750 for the nine months ended September 30, 2017 and 2016 respectively.

Note 4 - Due to Related Party

Note 4 - Due to Related Party	9 Months Ended
	Sep. 30, 2017
Notes
Note 4 - Due to Related Party	NOTE 4 – DUE TO RELATED PARTY As of September 30, 2017 and December 31, 2016, the Company owed HEP Investments, LLC, a related party, cumulative balances of $478,534 and $319,234, respectively. The basis for the payable is a 5.4% cash finance fee for monies invested in the Company in the form of convertible debt. For nine months ended September 30, 2017 and 2016, the Company incurred finance costs related to these transactions of $189,000 and $94,500, respectively.

Note 5 - Loan Payable, Related

Note 5 - Loan Payable, Related Parties	9 Months Ended
	Sep. 30, 2017
Notes
Note 5 - Loan Payable, Related Parties	NOTE 5 – LOAN PAYABLE, RELATED PARTIES Christopher Maggiore During the year ended December 31, 2016, Mr. Christopher Maggiore, a director and a significant shareholder of the Company, advanced the Company $20,000, for a total owed of $176,405. The Company has agreed to pay 11% interest on this loan. As of September 30, 2017 and December 31, 2016, accrued interest on this indebtedness totaled $59,652 and $40,231, respectively, and is included in Accrued Liabilities on the Condensed Consolidated Balance Sheet. HEP Investments, LLC In addition to amounts owed to HEP Investments pursuant to Convertible Debt (see Note 6), as of January 1, 2016, the Company owed HEP Investments $178,702. During the year ended December 31, 2016, HEP Investments loaned the Company an additional $1,890,872. Pursuant to the terms of the agreement with HEP Investments, $2,000,000 of these loans were recorded as 11% Convertible Secured Promissory Notes, leaving a remaining balance of $69,574 as of December 31, 2016. During the nine months ended September 30, 2017, HEP Investments loaned the Company $3,598,040 (see Note 6 - Convertible Debt). Pursuant to the terms of our agreement with HEP Investments, $3,500,000 of these loans were converted to 11% Convertible Secured Promissory Notes, leaving a remaining balance of $167,614 as of September 30, 2017.

Note 6 - Convertible Debt

Note 6 - Convertible Debt	9 Months Ended
	Sep. 30, 2017
Notes
Note 6 - Convertible Debt	NOTE 6 – CONVERTIBLE DEBT HEP Investments, LLC On December 2, 2011, the Company and HEP Investments, LLC, a Michigan limited liability company (“Lender”), entered into the following documents, effective as of December 1, 2011, as amended through March 1, 2017: (i) a Loan Agreement under which the Lender has agreed to advance up to $17,500,000 to the Company, subject to certain conditions, (ii) a Convertible Secured Promissory Note in the principal amount of $17,500,000 (“Note”) (of which $15,941,839 has been advanced as of September 30, 2017), (iii) a Security Agreement, under which the Company granted the Lender a security interest in all of its assets, (iv) issue the Lender warrants to purchase 1,666,667 shares of common stock at an exercise price of $.12 per share (including a cashless exercise provision) expiring September 30, 2016 (from the original December 1, 2011 agreement), (v) enter into a Registration Rights Agreement with respect to all the shares of common stock issuable to the Lender in connection with the Loan transaction, in each case subject to completion of funding of the full $2,000,000 called for by the Loan Agreement,. and (vi) an Intellectual Property security agreement under which the Company and its subsidiaries granted the Lender a security interest in all their respective intellectual properties, including patents, in order to secure their respective obligations to the Lender under the Note and related documents. In addition, the Company’s subsidiaries have guaranteed the Company’s obligations under the Note. The Company has also made certain agreements with the Lender which shall remain in effect as long as any amount is outstanding under the Loan. These agreements include an agreement not to make any change in the Company’s senior management, without the prior written consent of the Lender. Two representatives of the Lender will have the right to attend Board of Director meetings as non-voting observers. During the nine months ended September 30, 2016, the Company recorded debt discounts, related to $1,750,000 of Notes in the amount of $91,287, to reflect the relative fair value of the related warrants pursuant to "FASB ASC 470-20-30 – Debt with Conversion and Other Options: Beneficial Conversion Features" as a reduction to the carrying amount of the convertible debt and an addition to additional paid-in capital. The $1,750,000 of Notes are convertible at $.10 per share. The Company is amortizing the debt discount over the term of the debt. Amortization of the debt discounts was $1,119,875 for the nine months ended September 30, 2016. In the March 1, 2017 agreements, the Company and the Lender, also entered into the following documents: (i) Eighth Amendment to Loan Agreement under which the Lender has agreed to advance up to a total of $17,500,000 to the Company, subject to certain conditions, and (ii) a Ninth Amended and Restated Senior Secured Convertible Promissory Note. The Eighth Amendment to Loan Agreement amends and restates the Seventh Amendment to Loan Agreement, which was entered into with the Lender on December 31, 2015 and disclosed in the Company’s Form 8-K Current Report filed on January 7, 2016. The Ninth Amended and Restated Senior Secured Convertible Promissory Note resets the total outstanding debt as of March 1, 2017 and provides for a maturity date of September 30, 2018. The total outstanding debt as of March 1, 2017 was $12,721,839. The amount includes unpaid principal of $9,427,200, interest outstanding as of February 28, 2017 of $2,694,639 and restructuring and legal fees of $600,000. The Company recorded a debt discount of $600,000 related to the restructuring of the $12,721,839, 11% convertible note on March 1, 2017. The stated rate of the new debt was unchanged from the previous debt agreement and the estimated fair value of the new debt approximates its carrying amount (principal plus accrued interest at the date of the modification). In accordance with FASB ASC 470-60 “Debt-Troubled Debt Restructurings by Debtors,” the Company recorded a “Loss on Extinguishment of Debt” on March 1, 2017 of $406,482 which represented the remaining unamortized discount as of March 1, 2017. The Company, as consideration for the extension of the maturity date to September 30, 2018, agreed to change the conversion price of the $12,721,839 Convertible Promissory Note from conversion prices ranging from $.10 to $.30 per share to $.10 per share. The Company has agreed to pay a closing fee of $109,634 in connection with the Loan transaction (when the remaining $1,218,161 in funding is achieved), consisting of $65,781 in cash and $43,854 paid in shares of common stock valued at various amounts based on the timing of the funding and the related stock price. The related indebtedness represented by this convertible note shall be paid to the Lender in monthly installments of interest only beginning on July 1, 2017 and continuing on the first day of each month thereafter. As of September 30, 2017, the Company has not made any interest payments. The Company has received an extension of 3 months to pay the interest expense, to December 31, 2017. On March 3, 2017, as a result of the settlement of litigation with a shareholder, HEP Investments agreed to reduce the principal due to the Lender by $280,000 (see Note 10). On July 19, 2017, the Board of Directors approved the issuance to Lender of a warrant to purchase 50 million shares of common stock at a exercise price of $.10 for a term of two years on the basis of $2.5 million funding through the 11% convertible note (at a conversion price of $.10). This warrant is in addition to 10% warrant coverage (five-year term) provided to Lender in connection with investments in convertible debt pursuant to existing agreements. The warrant will not be issued until the related funding is complete. The warrant has a cashless exercise provision. In an agreement dated July 21, 2017 (“Agreement”) between Lender and Strome Mezzanine Fund LP (“Participant”), the Participant agreed to fund a total of $1.5 million ("the committed funding"), through the Lender’s 11% convertible note (at a conversion price of $.10). The Company also agreed to a “Right of First Refusal” (ROFR) with the Participant. The Company would give the Participant the ROFR to invest funds into the Company on the same terms and conditions (“Right of Participation”) as negotiated by the Company with a third party, provided that the Right of Participation must be exercised within 10 days. Certain exclusions apply relating to the committed funding from parties unrelated to the Participant. This ROFR terminates on the third (3) anniversary of the Agreement or if the participant fails to fund the full $1.5 million by November 20, 2017. The Participant has an agreement with the Lender that upon the funding of the Participant’s $1.5 million by November 20, 2017, the Lender would allocate a portion (50%) of the warrant to purchase 50 million shares of common stock at a conversion price of $.10 issued to the Lender on the $2.5 million funding through the 11% convertible note as discussed above. On July 24, 2017 the Lender funded $1,000,000 of the $2.5 million (of which $500,000 is from the Lender and $500,000 is from the Participant). Due to this additional funding, the Company issued to the Lender a $1,000,000, 11% convertible note (at a conversion price of $.10) and warrants to purchase 1,000,000 shares of common stock, at a conversion `price of $.10 for a term of five years. On September 25, 2017 the Lender funded an additional $1,000,000 of the $2.5 million (of which $500,000 is from the Lender and $500,000 is from the Participant). Due to this additional funding, the Company issued to the Lender a $1,000,000, 11% convertible note (at a conversion price of $.10) and warrants to purchase 1,000,000 shares of common stock, at a conversion `price of $.10 for a term of five years. (See Note 11 - Subsequent Events). During the nine months ended September 30, 2017, the Company recorded debt discounts, related to $3,500,000 of Notes in the amount of $225,453, to reflect the relative fair value of the related warrants pursuant to "FASB ASC 470-20-30 – Debt with Conversion and Other Options: Beneficial Conversion Features" as a reduction to the carrying amount of the convertible debt and an addition to additional paid-in capital. The $3,500,000 of Notes are convertible at $.10 per share. The Company is amortizing the debt discount over the term of the debt. Amortization of the debt discounts was $426,712 for the nine months ended September 30, 2017. If the Lender converted the total principal of $15,911,839 convertible debt as of September 30, 2017, the total shares of common stock to be issued would be 159,118,390 shares, not including the related accrued and any future interest charges which may be converted into common stock. Paulson Investment Company, LLC - Related Debt On August 24, 2016, the Company entered into a Placement Agent Agreement with Paulson Investment Company, LLC (Paulson). This agreement provides that Paulson can provide up to $2 million in financings through “accredited investors” (as defined by Regulation D of the Securities Act of 1933, as amended). As of December 31, 2016, the Company received funding of $1,250,000 through seven (7) individual loans (the “New Lenders”). Each loan includes a (i) a Loan Agreement relating to the individual loan, (ii) a Convertible Secured Promissory Note (“New Lenders Notes”) in the principal amount of the loan, (iii) a Security Agreement under which the Company granted the Lender a security interest in all of its assets and (iv) an Intercreditor Agreement with HEP Investments, LLC (HEP) whereby HEP and the New Lenders agree to participate in all collateral a pari passu The New Lenders Notes are convertible into the Company’s common stock at $.10 per share and bear interest at the rate of 11% per annum. The New Lenders Notes must be repaid as follows: accrued interest must be paid on the first and second anniversary of the Note and unpaid principal not previously converted into common stock must be repaid on the second anniversary of the Note. Other Debt In September 2014, the Lender agreed to rolling 30 day extensions until notice is given to the Company to the contrary. The Company determined that the modification of these Notes was not a substantial modification in accordance with ASC 470-50, “Modifications and Extinguishments.” Convertible debt consists of the following: September 30, 2017 December 31, 2016 (Unaudited) 1% Convertible notes payable, due October 2017 $ 240,000 $ 240,000 11% Convertible note payable – HEP Investments, a related party, net of unamortized discount of $565,788 and $574,443 at September 30, 2017 and December 31, 2016, respectively, due September 2018 (at September 30, 2017). 15,346,051 8,572,757 11% Convertible note payable – New Lenders; placed by Paulson, due at various dates ranging from September 2018 to October 2018 1,250,000 1,250,000 16,836,051 10,062,757 Less: Current portion 16,186,051 6,886,710 Long term portion $ 650,000 $ 3,176,047 Amortization of debt discounts was $427,626 and $1,119,875 for the nine months ended September 30, 2017 and 2016, respectively.

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit	9 Months Ended
	Sep. 30, 2017
Notes
Note 7 - Stockholders' Deficit	NOTE 7 - STOCKHOLDERS’ DEFICIT Board of Directors fees As compensation for serving as a member of the board of directors, the Company granted warrants to purchase 125,000 shares of common stock to Robert O. Rondeau, a new Director, in March 2016, at an exercise price of $.09 per share. The warrants have a term of five years and vested immediately. The warrants were valued at $10,588 using the Black Scholes pricing model relying on the following assumptions: volatility 168.01%; annual rate of dividends 0%; discount rate 0.97%. In addition, Mr. Rondeau will receive $10,000 for each annual term served, paid quarterly. On September 10, 2016, the board of directors granted to each of its Directors warrants to purchase 250,000 shares of common stock at an exercise price of $.05 per share. The warrants have a term of five years and vest immediately. The warrants were valued at $59,125 using the Black Scholes pricing model relying on the following assumptions: volatility 171.58%; annual rate of dividends 0%; discount rate 0.79%. In addition, each director is entitled to receive $10,000 for each annual term served. On September 11, 2017, the board of directors granted to each of its Directors warrants to purchase 500,000 shares of common stock at an exercise price of $.07 per share. The warrants have a term of five years and vest immediately. The warrants were valued at $166,668 using the Black Scholes pricing model relying on the following assumptions: volatility 175.54%; annual rate of dividends 0%; discount rate 1.71%. In addition, each director is entitled to receive $10,000 for each annual term served. The Company recorded directors’ fees of $196,668 and $99,713 for the nine months ended September 30, 2017 and 2016, respectively, representing the cash fees and the value of the vested warrants described above. Stock Based Compensation During the nine months ended September 30, 2016, the Company issued warrants to purchase 14,500,000 shares of common stock at an exercise price of $.08 with a term of 5 years pursuant to agreements with financial consultants. The warrants were valued at $1,095,063 using the Black Scholes pricing model relying on the following assumptions: volatility 170.07%; annual rate of dividends 0%; discount rate 0.89%. The Company also issued 3,500,000 shares of common stock, valued at $175,000, to an investor relations consulting firm. On April 18, 2017, the Company entered into a Limited License Agreement (“License Agreement”) with NutriQuest, LLC ("NutriQuest"), as disclosed in a Form 8-K filed on April 26, 2017. Pursuant to the agreement, the Company issued NutriQuest warrants to purchase 687,227 shares of common stock valued at $45,662 using the Black Scholes pricing model relying on the following assumptions: volatility 175.75%; annual rate of dividends 0%; discount rate 1.78%. The warrants are exercisable at $.08 per share and expire five (5) years from the date of issuance. The License Agreement provides that the Company is obligated to pay a termination fee to NutriQuest if the parties are unable to agree upon quality and volume delivered standards. During the nine months ended September 30, 2017, the Company issued warrants to purchase 17,000,000 shares of common stock. In the first quarter, the Company issued warrants to purchase 500,000 shares of common stock at an exercise price of $.10 with a term of 5 years pursuant to an agreement as a financial consultant. The warrants were valued at $33,148 using the Black Scholes pricing model relying on the following assumptions: volatility 175.05%; annual rate of dividends 0%; discount rate 1.87%. In the third quarter, the Company issued warrants to purchase 16,250,000 shares of common stock at an exercise price of $.06 to $.07 with a term of 5 years pursuant to agreements with financial consultants. The warrants were valued at $923,430 using the Black Scholes pricing model relying on the following assumptions: volatility 175.61% to 175.58%; annual rate of dividends 0%; discount rate 1.63% to 1.79%. Also, in the third quarter, the Company issued warrants to purchase 250,000 shares of common stock at an at an exercise price of $.07 with a term of 5 years pursuant to an agreement with a research consultant. The warrants were valued at $16,667 using the Black Scholes pricing model relying on the following assumptions: volatility 175.61%; annual rate of dividends 0%; discount rate 1.63%. Stock Issuances During the nine months ended September 30, 2016, in connection with the issuance of $2,350,000 in principal of 11% Convertible Debenture the Company issued 960,000 shares of common stock valued at $63,000 and warrants to purchase 2,712,500 shares of common stock at an exercise price of $.10 per share as financing costs related to the issuance of the 11% convertible debt. The warrants were valued at $113,231 using the Black Scholes pricing model relying on the following assumptions: volatility 158.5% to 172.8%; annual rate of dividends 0%; discount rate 0.75% to 0.85%. During the nine months ended September 30, 2017, in connection with the issuance of $3,500,000 in principal of 11% Convertible Debenture the Company issued to HEP Investments 1,735,714 shares of common stock valued at $126,000 and a five-year warrant to purchase 3,500,000 shares of common stock at an exercise price of $.10 per share. The Company also issued 250,000 shares of common stock valued at $22,500 as discussed in Note 10 - Settlement of Litigation – Related Party. Executive Compensation As compensation for serving as Chief Financial Officer, the Company, quarterly, issues warrants to purchase 50,000 shares of common stock to Philip M. Rice at the prevailing market price with a term of 5 years, provided that the preceding quarterly and annual filings were submitted in a timely and compliant manner, at which time such warrants would vest. On March 29, 2016, the Company issued warrants to purchase 50,000 shares of common stock at $.08. The warrants were valued at $3,771 using the Black Scholes pricing model relying on the following assumptions: volatility 169.28%; annual rate of dividends 0%; discount rate 0.78%. On May 13, 2016, the Company issued warrants to purchase 50,000 shares of common stock at $.08. The warrants were valued at $3,777 using the Black Scholes pricing model relying on the following assumptions: volatility 170.23%; annual rate of dividends 0%; discount rate 0.76%. On August 12, 2016, the Company issued warrants to purchase 50,000 shares of common stock at $.07. The warrants were valued at $3,307 using the Black Scholes pricing model relying on the following assumptions: volatility 170.83%; annual rate of dividends 0%; discount rate 0.71%. On March 31, 2017, the Company issued warrants to purchase 50,000 shares of common stock at $.08. The warrants were valued at $3,317 using the Black Scholes pricing model relying on the following assumptions: volatility 175.53%; annual rate of dividends 0%; discount rate 1.93%. On May 12, 2017, the Company issued warrants to purchase 50,000 shares of common stock at $.09. The warrants were valued at $4,283 using the Black Scholes pricing model relying on the following assumptions: volatility 176.74%; annual rate of dividends 0%; discount rate 1.93%. On August 11, 2017, the Company issued warrants to purchase 50,000 shares of common stock at $.06. The warrants were valued at $2,363 using the Black Scholes pricing model relying on the following assumptions: volatility 177.01%; annual rate of dividends 0%; discount rate 1.74%. Common Stock Warrants A summary of the status of the Company’s warrants is presented below. September 30, 2017 December 31, 2016 Number of Warrants Weighted Average Exercise Price Number of Warrants Weighted Average Exercise Price Outstanding, beginning of year 32,071,901 $ 0.13 14,705,818 $ 0.16 Issued 21,587,227 0.07 20,350,000 0.09 Exercised - - - - Cancelled - - - - Expired (1,507,374) 0.17 (2,983,917) 0.13 Outstanding, end of period 52,151,754 $ 0.08 32,071,901 $ 0.13 Warrants outstanding and exercisable by price range as of September 30, 2017 were as follows: Outstanding Warrants Exercisable Warrants Average Weighted Remaining Exercise Price Number Contractual Life in Years Exercise Price Number Weighted Average Exercise Price $ 0.05 1,250,000 3.95 $ 0.05 1,250,000 $ 0.05 0.06 16,050,000 4.87 0.06 16,050,000 0.06 0.07 3,000,000 4.95 0.07 3,000,000 0.07 0.08 18,612,227 3.50 0.08 18,612,227 0.08 0.09 759,110 4.78 0.09 759,110 0.09 0.10 9,427,200 3.55 0.10 9,427,200 0.10 0.12 50,000 2.87 0.12 50,000 0.12 0.14 50,000 1.87 0.14 50,000 0.14 0.15 1,376,941 1.93 0.15 1,376,941 0.15 0.17 50,000 1.50 0.17 50,000 0.17 0.19 50,000 1.62 0.19 50,000 0.19 0.22 269,276 1.00 0.22 269,276 0.22 0.25 707,000 0.63 0.25 707,000 0.25 0.30 250,000 1.18 0.30 250,000 0.30 0.33 250,000 0.75 0.33 250,000 0.33 52,151,754 3.89 52,151,754 $ 0.08

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Notes
Note 8 - Commitments and Contingencies	NOTE 8- COMMITMENTS AND CONTINGENCIES Employment Agreement The Company’s Chief Executive Officer, Andrew Dahl, is serving under the terms of an employment agreement dated December 16, 2011 as amended August 11, 2016. Under the agreement, Mr. Dahl serves as CEO for one year terms, subject to automatic renewal, unless either party terminates the Agreement on sixty days’ notice prior to the expiration of the term of the agreement. Mr. Dahl is compensated as follows: he receives an annual base salary of $240,000. In addition, Mr. Dahl is entitled to monthly bonus compensation equal to 2% of the Company’s revenue, but only to the extent that such bonus amount exceeds his base salary for the month in question. In addition, Mr. Dahl will be entitled to warrants having an exercise price of $.25 per share, upon the attainment of specified milestones as follows: 1) Warrants for 500,000 shares upon identification of bio-active agents in the Company’s product and filing of a patent with respect thereto, 2) Warrants for 500,000 shares upon entering into a business contract under which the Company receives at least $500,000 in cash payments, 3) Warrants for 1,000,000 shares upon the Company entering into a co-development agreement with a research company to develop medicinal or pharmaceutical applications (where the partner provides at least $2 million in cash or in-kind outlays), 4) Warrants for 1,000,000 shares upon the Company entering into a co-development agreement for nutraceutical or dietary supplement applications (where the partner provides at least $2 million in cash or in-kind outlays), 5) Warrants for 1,000,000 shares upon the Company entering into a pharmaceutical development agreement. Further, as it relates to Company’s wholly-owned subsidiary, WellMetris, LLC (“WellMetris”), in the event the Company ceases to own a controlling interest in WellMetris for any reason whatsoever, the Company shall cause WellMetris to grant Mr. Dahl warrants to purchase a seven percent (7%) equity interest in WellMetris at the time outside funding is closed and/or at the time an event occurs whereby the Company relinquishes majority control of WellMetris. Such Warrant shall be priced at the per-unit or per-share price at the time of the applicable closing or change of control with respect to WellMetris. As of September 30, 2017, none of the milestones referred to had been achieved and there has been no notice of contract termination. I nvestment Banking, M&A and Corporate Advisory Agreement On January 17, 2017 the Company entered into a one year agreement with an Investment Banking, Merger and Acquisition (M&A) and Corporate Advisory firm ("Firm"). Pursuant to the terms of the agreement, if the Company did not terminate the engagement prior to April 18, 2017, it was required to issue 1,875,000 shares of its common stock. As of April 18, 2017, the Company had not terminated the agreement and therefore became obligated to issue the aforementioned shares. The Company recorded the expense in Professional Fees and Consulting Expenses in the amount of $131,250 on its Condensed Consolidated Statement of Operations for the nine months ended September 30, 2017. In addition to the contract fee, the Company could potentially be required to be obligated to pay an 8% M&A transaction fee (as defined in the Agreement) payable in shares of the Company’s common stock (reduced by the value of the previously issued shares). Change of Control Provisions Effective as of April 21, 2017, the Board of Directors extended to December 31, 2017 the Change in Control Agreements (the “Agreements”) with both of its executive officers. The Agreements with each of the executive officers provide that if a Change of Control (as defined in the Agreements) occurs and the participant is not offered substantially equivalent employment with the successor corporation or the participant’s employment is terminated without Cause (as defined in the Agreements) during the three month period prior to the Change of Control or the 24 month period following the Change of Control, then 100% of such participant’s unvested options will be fully vested and the restrictions on his restricted shares will lapse. The Agreements also provide for severance payments of 500% of base salary and target bonus in such event. The Agreements terminate on December 31, 2017, with the provision that if a Change of Control occurs prior to the termination date, the obligations of the Agreements will remain in effect until they are satisfied or have expired.

Note 9 - Related Party Transact

Note 9 - Related Party Transactions	9 Months Ended
	Sep. 30, 2017
Notes
Note 9 - Related Party Transactions	NOTE 9 - RELATED PARTY TRANSACTIONS Due to Related Party See Note 4 Due to Related Party for disclosure of payable to related Party. Loan Payable – Related Party See Note 5 Loan Payable – Related Parties for disclosure of loans payable to related Parties Executive Compensation See Note 7 – Stockholder’ Deficiency for disclosure of compensation to the Chief Financial Officer. Employment Agreement See Note 8 – Commitments and Contingencies for disclosure of the Employment Agreement with the Chief Executive Officer.

Note 10 - Settlement of Litigat

Note 10 - Settlement of Litigation - Related Party	9 Months Ended
	Sep. 30, 2017
Notes
Note 10 - Settlement of Litigation - Related Party	NOTE 10 – SETTLEMENT OF LITIGATION - RELATED PARTY On July 15, 2015, a shareholder of the Company (“Shareholder”) brought action against HEP Investment alleging certain technical violations of Section 16(b) of the Securities Act of 1934, as amended. On March 3, 2017, without admitting any liability whatsoever, HEP Investment settled with the Shareholder by agreeing to reduce the Company’s debt owed to HEP Investment by $280,000. Related to this debt reduction, the Company paid to the Shareholder’s legal counsel $60,000 and 250,000 shares of the Company’s common stock valued at $22,500. The Company considered the settlement to be a Type 1 subsequent event and recorded legal fees of $82,500 on the Statement of Operations for the year ended December 31, 2016 and recorded the settlement amount of $280,000 as a reduction of convertible debt owed to HEP Investments and an increase to Additional Paid-In Capital on its Balance Sheet as of December 31, 2016.

Note 11 - Subsequent Events

Note 11 - Subsequent Events	9 Months Ended
	Sep. 30, 2017
Notes
Note 11 - Subsequent Events	NOTE 11 - SUBSEQUENT EVENTS 11% Convertible Debt - HEP Investments, LLC On October 18, 2017 the Company, HEP Investments, LLC (“Lender”) and Strome Mezzanine Fund LP (“Participant”) entered into an Amended and Restated Registration Rights Agreement (“Amended Agreement”). The Company and Lender are party to that certain Registration Rights Agreement, dated December 1, 2011 (“Original Agreement”) (filed as Exhibit 10.10 filed with the Company’s 2011 Form 10-K filed on March, 30, 2012). In an agreement dated July 21, 2017 (“Funding Agreement”) between Lender and Participant, the Participant agreed to fund a total of $1.5 million through the Lender’s 11% convertible note (at a conversion price of $.10) (see Note 6 – Convertible Debt). As a part of this Funding Agreement, the Lender and the Company agreed to amend and restate the Original Agreement. The Amended Agreement, among other items, reaffirms or grants, as applicable, registration rights to Lender and Participant. Further details are included in the Amended Agreement and filed as Exhibit 10.1 as a part of this Form 10-Q.

Note 2 - Summary of Significa18

Note 2 - Summary of Significant Accounting Policies: Principles of Consolidation (Policies)	9 Months Ended
	Sep. 30, 2017
Policies
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly-owned subsidiaries, Health Enhancement Corporation, HEPI Pharmaceuticals, Inc., WellMetris, LLC, and Zivo Biologic, Inc. All significant intercompany transactions and accounts have been eliminated in consolidation.

Note 2 - Summary of Significa19

Note 2 - Summary of Significant Accounting Policies: Accounting Estimates (Policies)	9 Months Ended
	Sep. 30, 2017
Policies
Accounting Estimates	Accounting Estimates The Company’s condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities, at the date of the financial statements and reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management uses its best judgment in valuing these estimates and may, as warranted, solicit external professional advice and other assumptions believed to be reasonable.

Note 2 - Summary of Significa20

Note 2 - Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies)	9 Months Ended
	Sep. 30, 2017
Policies
Cash and Cash Equivalents	Cash and Cash Equivalents For the purpose of the statements of cash flows, cash equivalents include time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. Cash equivalents consist of highly liquid investments with an original maturity of three months or less when purchased. At September 30, 2017, the Company did not have any cash equivalents.

Note 2 - Summary of Significa21

Note 2 - Summary of Significant Accounting Policies: Property and Equipment (Policies)	9 Months Ended
	Sep. 30, 2017
Policies
Property and Equipment	Property and Equipment Property and equipment consists of furniture and office equipment and are carried at cost less allowances for depreciation and amortization. Depreciation and amortization is determined by using the straight-line method over the estimated useful lives of the related assets. Repair and maintenance costs that do not improve service potential or extend the economic life of an existing fixed asset are expensed as incurred.

Note 2 - Summary of Significa22

Note 2 - Summary of Significant Accounting Policies: Deferred Financing Costs (Policies)	9 Months Ended
	Sep. 30, 2017
Policies
Deferred Financing Costs	Deferred Financing Costs The Company follows authoritative guidance for accounting for financing costs as it relates to convertible debt issuance cost. These costs are deferred and amortized over the term of the debt period or until redemption of the convertible debentures. Amortization of deferred financing costs amounted to $84,350 and $0 for the nine months ended September 30, 2017 and 2016, respectively.

Note 2 - Summary of Significa23

Note 2 - Summary of Significant Accounting Policies: Revenue Recognition (Policies)	9 Months Ended
	Sep. 30, 2017
Policies
Revenue Recognition	Revenue Recognition For revenue from product sales, the Company recognizes revenue in accordance with Staff Accounting Bulletin No. 104, “Revenue Recognition” (“SAB No. 104”), which superseded Staff Accounting Bulletin No. 101, “Revenue Recognition in Financial Statements” (“SAB No. 101”). SAB No. 104 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgment regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. For nine months ended September 30, 2017 and 2016, the Company had no revenue.

Note 2 - Summary of Significa24

Note 2 - Summary of Significant Accounting Policies: Shipping and Handling Costs (Policies)	9 Months Ended
	Sep. 30, 2017
Policies
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling costs are expensed as incurred. For the nine months ended September 30, 2017 and 2016, no shipping and handling costs were incurred.

Note 2 - Summary of Significa25

Note 2 - Summary of Significant Accounting Policies: Research and Development (Policies)	9 Months Ended
	Sep. 30, 2017
Policies
Research and Development	Research and Development Research and development costs are expensed as incurred. The majority of the Company's research and development costs consist of clinical study expenses. These consist of fees, charges, and related expenses incurred in the conduct of clinical studies conducted with Company products by independent outside contractors. External clinical studies expenses were approximately $1,355,000 and $601,000 for the nine months ended September 30, 2017 and 2016, respectively.

Note 2 - Summary of Significa26

Note 2 - Summary of Significant Accounting Policies: Stock Based Compensation (Policies)	9 Months Ended
	Sep. 30, 2017
Policies
Stock Based Compensation	Stock Based Compensation We account for stock-based compensation in accordance with FASB ASC 718, Compensation – Stock Compensation. During the nine months ended September 30, 2017 and 2016, warrants were granted to employees and consultants of the Company. As a result of these grants, the Company recorded compensation expense of $1,337,289 and $1,175,630 for these periods, respectively. The fair value of warrants was estimated on the date of grant using the Black-Scholes option-pricing model based on the following weighted average assumptions: Nine Months Ended September 30, 2017 2016 Expected volatility 175.05% to 177.58% 158.53% to 172.80% Expected dividends 0% 0% Expected term 5 years 5 years Risk free rate 1.63% to 1.93% .71% to .97% The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, option-pricing models require the input of highly subjective assumptions, including the expected stock price volatility. Because the Company’s employee warrants have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion the existing models may not necessarily provide a reliable single measure of the fair value of the warrants.

Note 2 - Summary of Significa27

Note 2 - Summary of Significant Accounting Policies: Loss Per Share (Policies)	9 Months Ended
	Sep. 30, 2017
Policies
Loss Per Share	Loss Per Share Basic loss per share is computed by dividing the Company’s net loss by the weighted average number of common shares outstanding during the period presented. Diluted loss per share is based on the treasury stock method and includes the effect from potential issuance of common stock such as shares issuable pursuant to the exercise of warrants and conversions of debentures. Potentially dilutive securities as September 30, 2017, consisted of 186,314,359 common shares issuable upon the conversion of convertible debentures and related accrued interest and 52,151,754 common shares issuable upon the exercise of outstanding warrants. Potentially dilutive securities as of September 30, 2016, consisted of 102,036,360 common shares issuable upon the conversion of convertible debentures and related accrued interest and 30,167,488 common shares issuable upon the exercise of outstanding warrants. For the nine months ended September 30, 2017 and 2016 diluted and basic weighted average shares are the same, as potentially dilutive shares are anti-dilutive.

Note 2 - Summary of Significa28

Note 2 - Summary of Significant Accounting Policies: Advertising (Policies)	9 Months Ended
	Sep. 30, 2017
Policies
Advertising	Advertising Advertising costs are charged to operations when incurred. There were no advertising costs for the nine months ended September 30, 2017 and 2016.

Note 2 - Summary of Significa29

Note 2 - Summary of Significant Accounting Policies: Concentrations of Credit Risk (Policies)	9 Months Ended
	Sep. 30, 2017
Policies
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company, from time to time, maintains cash balances at financial institutions which exceed the current Federal Deposit Insurance Corporation (“FDIC”) limit of $250,000.

Note 2 - Summary of Significa30

Note 2 - Summary of Significant Accounting Policies: Reclassifications (Policies)	9 Months Ended
	Sep. 30, 2017
Policies
Reclassifications	Reclassifications Certain items in these consolidated financial statements have been reclassified to conform to the current period presentation.

Note 2 - Summary of Significa31

Note 2 - Summary of Significant Accounting Policies: Future Impact of Recently Issued Accounting Standards (Policies)	9 Months Ended
	Sep. 30, 2017
Policies
Future Impact of Recently Issued Accounting Standards	Future Impact of Recently Issued Accounting Standards In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2014-09 (ASU 2014-09), “Revenue from Contracts with Customers.” ASU 2014-09 superseded the revenue recognition requirements in “Revenue Recognition (Topic 605)” and requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflect the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is not permitted. ASU 2014-09 is not expected to have a material impact on the Company’s financial position or results of operations. In August 2014, the FASB issued Accounting Standards Update 2014-15 (ASU 2014-15) “Presentation of Financial Statements – Going Concern (Subtopic 205-40).” The amendments in this Update are effective for the annual period ending after December 15, 2015, and for annual periods and interim periods thereafter. Early application is permitted. This Update had no effect on the Company’s financial position and results of operations for the year ended December 31, 2016. Management does not believe there would have been a material effect on the accompanying financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.

Note 2 - Summary of Significa32

Note 2 - Summary of Significant Accounting Policies: Stock Based Compensation: Schedule of Fair Value of Warrants (Tables)	9 Months Ended
	Sep. 30, 2017
Tables/Schedules
Schedule of Fair Value of Warrants	Nine Months Ended September 30, 2017 2016 Expected volatility 175.05% to 177.58% 158.53% to 172.80% Expected dividends 0% 0% Expected term 5 years 5 years Risk free rate 1.63% to 1.93% .71% to .97%

Note 3 - Property and Equipme33

Note 3 - Property and Equipment: Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2017
Tables/Schedules
Property, Plant and Equipment	September 30, 2017 December 31, 2016 (Unaudited) Furniture and fixtures $ 20,000 $ 20,000 Equipment 80,000 80,000 100,000 100,000 Less accumulated depreciation and amortization (100,000) (81,250) $ 0 $ 18,750

Note 6 - Convertible Debt_ Sche

Note 6 - Convertible Debt: Schedule of Convertible Debt (Tables)	9 Months Ended
	Sep. 30, 2017
Tables/Schedules
Schedule of Convertible Debt	Convertible debt consists of the following: September 30, 2017 December 31, 2016 (Unaudited) 1% Convertible notes payable, due October 2017 $ 240,000 $ 240,000 11% Convertible note payable – HEP Investments, a related party, net of unamortized discount of $565,788 and $574,443 at September 30, 2017 and December 31, 2016, respectively, due September 2018 (at September 30, 2017). 15,346,051 8,572,757 11% Convertible note payable – New Lenders; placed by Paulson, due at various dates ranging from September 2018 to October 2018 1,250,000 1,250,000 16,836,051 10,062,757 Less: Current portion 16,186,051 6,886,710 Long term portion $ 650,000 $ 3,176,047

Note 7 - Stockholders' Deficit_

Note 7 - Stockholders' Deficit: Schedule of Status of Warrants (Tables)	9 Months Ended
	Sep. 30, 2017
Tables/Schedules
Schedule of Status of Warrants	September 30, 2017 December 31, 2016 Number of Warrants Weighted Average Exercise Price Number of Warrants Weighted Average Exercise Price Outstanding, beginning of year 32,071,901 $ 0.13 14,705,818 $ 0.16 Issued 21,587,227 0.07 20,350,000 0.09 Exercised - - - - Cancelled - - - - Expired (1,507,374) 0.17 (2,983,917) 0.13 Outstanding, end of period 52,151,754 $ 0.08 32,071,901 $ 0.13

Note 7 - Stockholders' Defici36

Note 7 - Stockholders' Deficit: Schedule of Warrants outstanding and exercisable by price range (Tables)	9 Months Ended
	Sep. 30, 2017
Tables/Schedules
Schedule of Warrants outstanding and exercisable by price range	Outstanding Warrants Exercisable Warrants Average Weighted Remaining Exercise Price Number Contractual Life in Years Exercise Price Number Weighted Average Exercise Price $ 0.05 1,250,000 3.95 $ 0.05 1,250,000 $ 0.05 0.06 16,050,000 4.87 0.06 16,050,000 0.06 0.07 3,000,000 4.95 0.07 3,000,000 0.07 0.08 18,612,227 3.50 0.08 18,612,227 0.08 0.09 759,110 4.78 0.09 759,110 0.09 0.10 9,427,200 3.55 0.10 9,427,200 0.10 0.12 50,000 2.87 0.12 50,000 0.12 0.14 50,000 1.87 0.14 50,000 0.14 0.15 1,376,941 1.93 0.15 1,376,941 0.15 0.17 50,000 1.50 0.17 50,000 0.17 0.19 50,000 1.62 0.19 50,000 0.19 0.22 269,276 1.00 0.22 269,276 0.22 0.25 707,000 0.63 0.25 707,000 0.25 0.30 250,000 1.18 0.30 250,000 0.30 0.33 250,000 0.75 0.33 250,000 0.33 52,151,754 3.89 52,151,754 $ 0.08

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Details
Net Loss	$ (2,868,518)	$ (1,140,381)	$ (6,158,296)	$ (4,827,429)
Working capital deficiency	17,502,058		17,502,058
Accumulated Stockholders' Equity (Deficit)	$ 18,038,289		18,038,289
Issuance of convertible debt			$ 3,500,000

Note 2 - Summary of Significa38

Note 2 - Summary of Significant Accounting Policies: Deferred Financing Costs (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Details
Amortization of deferred financing costs	$ 84,350	$ 0

Note 2 - Summary of Significa39

Note 2 - Summary of Significant Accounting Policies: Stock Based Compensation (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Details
Allocated Share-based Compensation Expense	$ 1,337,289	$ 1,175,630

Note 2 - Summary of Significa40

Note 2 - Summary of Significant Accounting Policies: Stock Based Compensation: Schedule of Fair Value of Warrants (Details) - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Expected dividends	$ 0	$ 0
Expected term	5 years	5 years
Minimum
Expected volatility	175.05%	158.53%
Risk free rate	1.63%	0.71%
Maximum
Expected volatility	177.58%	172.80%
Risk free rate	1.93%	0.97%

Note 2 - Summary of Significa41

Note 2 - Summary of Significant Accounting Policies: Loss Per Share (Details) - shares	Sep. 30, 2017	Sep. 30, 2016
Details
Potentially dilutive securities, Common shares from convertible debentures	186,314,359	102,036,360
Potentially dilutive securities, Common shares from outstanding warrants	52,151,754	30,167,488

Note 2 - Summary of Significa42

Note 2 - Summary of Significant Accounting Policies: Advertising (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Details
Advertising Expense	$ 0	$ 0

Note 3 - Property and Equipme43

Note 3 - Property and Equipment: Property, Plant and Equipment (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Details
Furniture and fixtures	$ 20,000	$ 20,000
Equipment	80,000	80,000
Property, Plant and Equipment, Gross	100,000	100,000
Less accumulated depreciation and amortization	(100,000)	(81,250)
PROPERTY AND EQUIPMENT, NET	$ 0	$ 18,750

Note 3 - Property and Equipme44

Note 3 - Property and Equipment (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Details
Depreciation, Depletion and Amortization, Nonproduction	$ 18,750	$ 18,750

Note 4 - Due to Related Party (

Note 4 - Due to Related Party (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Due to Related Party	$ 478,534		$ 319,234
Finance costs related to Related Parties	189,000	$ 94,500
HEP Investments, LLC
Due to Related Party	$ 478,534		$ 319,234

Note 5 - Loan Payable, Relate46

Note 5 - Loan Payable, Related Parties (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Accrued Interest	$ 1,163,827	$ 2,659,574
Christopher Maggiore
Loan balance due to Related Parties		176,405
Accrued Interest	59,652	40,231
HEP Investments, LLC
Loan balance due to Related Parties	$ 167,614	$ 69,574

Note 6 - Convertible Debt_ Sc47

Note 6 - Convertible Debt: Schedule of Convertible Debt (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Details
1% Convertible notes payable, due April 2017	$ 240,000	$ 240,000
11% Convertible note payable	15,346,051	8,572,757
11% Convertible note payable - New Lenders	1,250,000	1,250,000
Convertible Debt, Total	16,836,051	10,062,757
Current portion	16,186,051	6,886,710
Long term portion	$ 650,000	$ 3,176,047

Note 6 - Convertible Debt (Deta

Note 6 - Convertible Debt (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Details
Amortization of debt discounts	$ 427,626	$ 1,119,875

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Details
Directors' fees	$ 196,668	$ 99,713
Warrants issued to purhase common stock, Value	$ 33,148

Note 7 - Stockholders' Defici50

Note 7 - Stockholders' Deficit: Schedule of Status of Warrants (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Details
Warrants Outstanding	32,071,901	14,705,818
Warrants Outstanding, Weighted Average Exercise Price	$ 0.13	$ 0.16
Warrants Issued	21,587,227	20,350,000
Warrants Issued, Weighted Average Exercise Price	$ 0.07	$ 0.09
Warrants Cancelled	0	0
Warrants Cancelled, Weighted Average Exercise Price	$ 0	$ 0
Warrants Expired	(1,507,374)	(2,983,917)
Warrants Expired, Weighted Average Exercise Price	$ 0.17	$ 0.13
Warrants Outstanding	52,151,754	32,071,901
Warrants Outstanding, Weighted Average Exercise Price	$ 0.08	$ 0.13

Note 7 - Stockholders' Defici51

Note 7 - Stockholders' Deficit: Schedule of Warrants outstanding and exercisable by price range (Details)	Sep. 30, 2017$ / shares
Warrant 1
Warrants Outstanding, Exercise Price	$ 0.05
Warrants Outstanding, Number	1,250,000
Warrants Outstanding, Average Weighted Remaining Contractual Life in Years	3.95
Warrants Exercisable, Exercise Price	$ 0.05
Warrants Exercisable, Number	1,250,000
Warrants Exercisable, Average Weighted Remaining Contractual Life in Years	0.05
Warrant 2
Warrants Outstanding, Exercise Price	$ 0.06
Warrants Outstanding, Number	16,050,000
Warrants Outstanding, Average Weighted Remaining Contractual Life in Years	4.87
Warrants Exercisable, Exercise Price	$ 0.06
Warrants Exercisable, Number	16,050,000
Warrants Exercisable, Average Weighted Remaining Contractual Life in Years	0.06
Warrant 3
Warrants Outstanding, Exercise Price	$ 0.07
Warrants Outstanding, Number	3,000,000
Warrants Outstanding, Average Weighted Remaining Contractual Life in Years	4.95
Warrants Exercisable, Exercise Price	$ 0.07
Warrants Exercisable, Number	3,000,000
Warrants Exercisable, Average Weighted Remaining Contractual Life in Years	0.07
Warrant 4
Warrants Outstanding, Exercise Price	$ 0.08
Warrants Outstanding, Number	18,612,227
Warrants Outstanding, Average Weighted Remaining Contractual Life in Years	3.50
Warrants Exercisable, Exercise Price	$ 0.08
Warrants Exercisable, Number	18,612,227
Warrants Exercisable, Average Weighted Remaining Contractual Life in Years	0.08
Warrant 5
Warrants Outstanding, Exercise Price	$ 0.09
Warrants Outstanding, Number	759,110
Warrants Outstanding, Average Weighted Remaining Contractual Life in Years	4.78
Warrants Exercisable, Exercise Price	$ 0.09
Warrants Exercisable, Number	759,110
Warrants Exercisable, Average Weighted Remaining Contractual Life in Years	0.09
Warrant 6
Warrants Outstanding, Exercise Price	$ 0.10
Warrants Outstanding, Number	9,427,200
Warrants Outstanding, Average Weighted Remaining Contractual Life in Years	3.55
Warrants Exercisable, Exercise Price	$ 0.10
Warrants Exercisable, Number	9,427,200
Warrants Exercisable, Average Weighted Remaining Contractual Life in Years	0.10
Warrant 7
Warrants Outstanding, Exercise Price	$ 0.12
Warrants Outstanding, Number	50,000
Warrants Outstanding, Average Weighted Remaining Contractual Life in Years	2.87
Warrants Exercisable, Exercise Price	$ 0.12
Warrants Exercisable, Number	50,000
Warrants Exercisable, Average Weighted Remaining Contractual Life in Years	0.12
Warrant 8
Warrants Outstanding, Exercise Price	$ 0.14
Warrants Outstanding, Number	50,000
Warrants Outstanding, Average Weighted Remaining Contractual Life in Years	1.87
Warrants Exercisable, Exercise Price	$ 0.14
Warrants Exercisable, Number	50,000
Warrants Exercisable, Average Weighted Remaining Contractual Life in Years	0.14
Warrant 9
Warrants Outstanding, Exercise Price	$ 0.15
Warrants Outstanding, Number	1,376,941
Warrants Outstanding, Average Weighted Remaining Contractual Life in Years	1.93
Warrants Exercisable, Exercise Price	$ 0.15
Warrants Exercisable, Number	1,376,941
Warrants Exercisable, Average Weighted Remaining Contractual Life in Years	0.15
Warrant 10
Warrants Outstanding, Exercise Price	$ 0.17
Warrants Outstanding, Number	50,000
Warrants Outstanding, Average Weighted Remaining Contractual Life in Years	1.50
Warrants Exercisable, Exercise Price	$ 0.17
Warrants Exercisable, Number	50,000
Warrants Exercisable, Average Weighted Remaining Contractual Life in Years	0.17
Warrant 11
Warrants Outstanding, Exercise Price	$ 0.19
Warrants Outstanding, Number	50,000
Warrants Outstanding, Average Weighted Remaining Contractual Life in Years	1.62
Warrants Exercisable, Exercise Price	$ 0.19
Warrants Exercisable, Number	50,000
Warrants Exercisable, Average Weighted Remaining Contractual Life in Years	0.19
Warrant 12
Warrants Outstanding, Exercise Price	$ 0.22
Warrants Outstanding, Number	269,276
Warrants Outstanding, Average Weighted Remaining Contractual Life in Years	1
Warrants Exercisable, Exercise Price	$ 0.22
Warrants Exercisable, Number	269,276
Warrants Exercisable, Average Weighted Remaining Contractual Life in Years	0.22
Warrant 13
Warrants Outstanding, Exercise Price	$ 0.25
Warrants Outstanding, Number	707,000
Warrants Outstanding, Average Weighted Remaining Contractual Life in Years	0.63
Warrants Exercisable, Exercise Price	$ 0.25
Warrants Exercisable, Number	707,000
Warrants Exercisable, Average Weighted Remaining Contractual Life in Years	0.25
Warrant 14
Warrants Outstanding, Exercise Price	$ 0.30
Warrants Outstanding, Number	250,000
Warrants Outstanding, Average Weighted Remaining Contractual Life in Years	1.18
Warrants Exercisable, Exercise Price	$ 0.30
Warrants Exercisable, Number	250,000
Warrants Exercisable, Average Weighted Remaining Contractual Life in Years	0.30
Warrant 15
Warrants Outstanding, Exercise Price	$ 0.33
Warrants Outstanding, Number	250,000
Warrants Outstanding, Average Weighted Remaining Contractual Life in Years	0.75
Warrants Exercisable, Exercise Price	$ 0.33
Warrants Exercisable, Number	250,000
Warrants Exercisable, Average Weighted Remaining Contractual Life in Years	0.33
Warrants Outstanding, Number	52,151,754
Warrants Outstanding, Average Weighted Remaining Contractual Life in Years	3.89
Warrants Exercisable, Number	52,151,754
Warrants Exercisable, Average Weighted Remaining Contractual Life in Years	0.08

Note 8 - Commitments and Cont52

Note 8 - Commitments and Contingencies (Details)	9 Months Ended
	Sep. 30, 2017
Investment Banking, M&A and Corporate Advisory Agreement
Other Commitments, Description	In addition to the contract fee, the Company could potentially be required to be obligated to pay an 8% M&A transaction fee
Change of Control Provisions
Other Commitments, Description	The Agreements with each of the executive officers provide that if a Change of Control (as defined in the Agreements) occurs and the participant is not offered substantially equivalent employment with the successor corporation or the participant’s employment is terminated without Cause (as defined in the Agreements) during the three month period prior to the Change of Control or the 24 month period following the Change of Control, then 100% of such participant’s unvested options will be fully vested and the restrictions on his restricted shares will lapse.

Note 10 - Settlement of Litig53

Note 10 - Settlement of Litigation - Related Party (Details)	Dec. 31, 2016USD ($)
Details
Reduction of Convertible Debt	$ 280,000

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details)	9 Months Ended
	Sep. 30, 2017
Details
Subsequent Event, Date	Oct. 18, 2017
Subsequent Event, Description	the Company, HEP Investments, LLC (“Lender”) and Strome Mezzanine Fund LP (“Participant”) entered into an Amended and Restated Registration Rights Agreement